Author

Esther García-Planella

THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL
THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL

Esther García-Planella  et al.

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

Esther García-Planella  et al.

IMMUNOSUPPRESSIVE TREATMENT IS NOT A RISK FACTOR TO DEVELOP A WORSE SARS-COV-2 INFECTION IN ELDERLY IBD PATIENTS. AN OBSERVATIONAL, DESCRIPTIVE, COHORT STUDY
IMMUNOSUPPRESSIVE TREATMENT IS NOT A RISK FACTOR TO DEVELOP A WORSE SARS-COV-2 INFECTION IN ELDERLY IBD PATIENTS. AN OBSERVATIONAL, DESCRIPTIVE, COHORT STUDY

Esther García-Planella  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Esther García-Planella  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Esther García-Planella  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Esther García-Planella  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Esther García-Planella  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Esther García-Planella  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Esther García-Planella  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Esther García-Planella  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Esther García-Planella  et al.

Item 1 - 11 / 11
1